Opendata, web and dolomites

TrojanDC SIGNED

TrojanDC

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TrojanDC project word cloud

Explore the words cloud of the TrojanDC project. It provides you a very rough idea of what is the project "TrojanDC" about.

acquisitions    effectiveness    2024    demand    paradigm    overhaul    car    global    reprogramming    patients    therapy    strategy    immunotherapy    14    entrepreneurs       start    maximizing    tumoral    reliably    seasoned    costing    personalized    viral    technologies    patient    effector    proof    cancer    consistently    combination    therapeutics    health    uses    market    fastest    dendritic    350k    data    presenting    vivo    keen    gene    company    size    something    urgent    immunotherapies    grant    form    shown    performing    cells    shortcomings    limited    114    oncology    locked    re    merck    vector    players    develops    founded    asgard    inducing    swedish    bms    diversity    scientists    efficacy    transcription    cagr    commercialization    sme    immune    trojandc    immunogenic    team    despite    critical    resistance    markets    proprietary    instrument    sound    antigens    roche    injection    innovative    fits    lose    cell    named    genes    shifting    balanced    tumor    delivers    heterogeneous    antigen    price    anti    eradicate    educates    chances    robustly    approx   

Project "TrojanDC" data sheet

The following table provides information about the project.

Coordinator
ASGARD THERAPEUTICS AB 

Organization address
address: REVINGEGATAN 19C 1203
city: LUND
postcode: 223 59
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASGARD THERAPEUTICS AB SE (LUND) coordinator 50˙000.00

Map

 Project objective

Asgard Therapeutics, a Swedish start-up company, was founded based on a unique proprietary in vivo cell reprogramming technology. This paradigm-shifting gene therapy has the unique potential to overhaul the cancer immunotherapy market.

Our gene therapy, named TrojanDC, delivers immune-genes into the tumor and re-educates cancer cells to become anti-tumor immune cells. It uses a viral vector to deliver a unique combination of three critical transcription factors (genes) through intra-tumoral injection. The transcription factors make cancer cells become antigen-presenting dendritic cells. These immunogenic cells present their own diversity of tumor-specific antigens to effector immune cells, reliably and robustly inducing immune responses that eradicate the heterogeneous tumor.

Cancer remains a major health challenge. Currently available immunotherapies show strong effectiveness only in a limited number of patients, and often lose their efficacy as the tumor develops resistance. In addition, immunotherapies come with high price (e.g. CAR-T cell approach costing approx. € 350k/patient). Despite these shortcomings, the global immune-oncology market is one of the fastest growing therapeutics markets (€114.6 B by 2024 with a CAGR of 14.3%). Large players like BMS, Merck and Roche have shown to be keen on acquisitions of high-potential technologies. There is thus an urgent need and high demand for innovative cost-effective immunotherapies consistently effective in a broader range of cancer patients – something that Asgard Therapeutics will deliver with TrojanDC in the form of a personalized and highly specific immune therapy using a ‘one-size-fits-all’ approach.

With in-vivo proof-of-concept data already obtained and a balanced team of high-performing scientists and seasoned entrepreneurs, Asgard Therapeutics has locked up key factors towards maximizing its chances of success. This SME instrument grant will ensure a sound strategy towards commercialization of TrojanDC.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TROJANDC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TROJANDC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

CyreenApplication (2019)

Connecting Ad-Impressions with Purchase. The new advanced Advertisement at the point of sales.

Read More